SiBionics Showcases Advanced CGM Solutions for Diabetes Management at EASD 2025
SiBionics Presents Innovative CGM Solutions for Diabetes at EASD 2025
The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna marked a significant milestone for SiBionics as it showcased its groundbreaking Continuous Glucose Monitoring (CGM) and Continuous Ketone Monitoring (CKM) systems. These integrated solutions have been developed with a focus on improving diabetes management, and they garnered positive recognition from global researchers and experts in the field.
Key Highlights from the Symposium
The symposium, titled “CGM + CKM for Better Diabetes Management,” facilitated insightful discussions among international experts. The event was co-chaired by Prof. Linong Ji from Peking University People’s Hospital and Prof. Stefano Genovese from Italy, who highlighted the potential of SiBionics’ solutions in transforming diabetes care.
Attendees included eminent scholars such as Prof. Andrej Janež from Slovenia, Prof. Nina Jendrike from Germany, and Dr. Yifei Mo from China, who shared the latest research findings at the event. The gathering emphasized the collective commitment of health professionals to innovate and improve diabetes management strategies using advanced technology.
The Future of Diabetes Management
SiBionics presented its next-generation devices: the GS3 CGM system and the KS3 CKM device. These products captured the attention of visitors at the exhibition, sparking engaging dialogues about their technical advantages and clinical relevance. Feedback from healthcare professionals indicated a strong interest in how these devices could be utilized in real-life diabetes treatment scenarios.
A feasibility study showcased that the GS3 system not only meets but also exceeds several key performance indicators linked to iCGM standards. Its accuracy and clinical reliability have been notably recognized, especially in hypoglycemic contexts where it outperformed expectations. This effectiveness further underlines its value in clinical decision-making and patient self-management, affirming SiBionics’ position as an emerging leader in continuous monitoring technologies.
Looking Ahead
As the only company currently marketing CKM solutions globally, SiBionics has demonstrated its exceptional R&D capabilities and innovative vision. The company plans to continue expanding its CXM portfolio, driving advancements in technology to deliver precise, high-quality solutions that aim to improve outcomes for individuals living with diabetes around the world.
About SiBionics
Founded in 2015, SiBionics is a forefront medical technology company based in Shenzhen and Irvine, specializing in innovations in biosensors. By merging continuous monitoring technology, intelligent algorithms, and user-friendly software, SiBionics aims to enhance health management for people with diabetes. Currently, the company employs over 500 individuals, with 25% in R&D, dedicated to providing personalized, data-driven care to improve the quality of life for patients.
For more information about SiBionics, please visit their website or connect with their press team via email.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.